Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial

Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J. L. Loosveld, M. Wouter Dercksen, Maartje Los, Marco B. Polee, Franchette van den Berkmortel, Maureen J. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, Johanna E. A. Portielje, Frank P. J. Peters, Heinz-Josef Kluempen, Vincent van der Noort, John B. A. G. Haanen, Emile E. Voest*, Dutch WIN-O Consortium

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalJAMA Oncology
Volume3
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • PHASE-III TRIAL
  • SUNITINIB RECHALLENGE
  • DRUG-RESISTANCE
  • CARCINOMA
  • THERAPY
  • SURVEILLANCE
  • GUIDELINES
  • EFFICACY

Cite this

Cirkel, G. A., Hamberg, P., Sleijfer, S., Loosveld, O. J. L., Dercksen, M. W., Los, M., Polee, M. B., van den Berkmortel, F., Aarts, M. J., Beerepoot, L. V., Groenewegen, G., Lolkema, M. P., Tascilar, M., Portielje, J. E. A., Peters, F. P. J., Kluempen, H-J., van der Noort, V., Haanen, J. B. A. G., Voest, E. E., & Dutch WIN-O Consortium (2017). Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial. JAMA Oncology, 3(4), 501-508. https://doi.org/10.1001/jamaoncol.2016.5202